May 2025 in “Journal of Drug Delivery and Therapeutics” Combining modern and Unani medicine may improve BPH treatment with fewer side effects.
Combined finasteride and anastrozole therapy effectively treats BPH, influenced by hormone imbalances and genetics.
January 2013 in “Journal of Chengdu Medical College” Tolterodine Tartrate effectively treats overactive bladder symptoms.
7 citations
,
October 2009 in “Journal of the American Geriatrics Society” Finasteride may help reduce inappropriate sexual behaviors in dementia patients with prostate issues.
11 citations
,
August 2014 in “Current Urology Reports” Medications for enlarged prostate can cause sexual side effects like reduced libido, erectile dysfunction, and ejaculatory problems.
1 citations
,
April 2023 in “World Journal of Urology” Finasteride reduces some inflammation in BPH but not all.
Tamsulosin and finasteride together effectively slow down and prevent BPH progression.
March 2014 in “Annals of Internal Medicine” Combining α1-blockers with 5α-reductase inhibitors improves urinary symptoms in men.
September 2025 in “Consilium Medicum” 5α-reductase inhibitors help manage symptoms of benign prostatic hyperplasia and may also prevent prostate cancer and treat hair loss.
26 citations
,
December 2023 in “Prostate International” Medications for BPH can have significant side effects, so understanding these risks is important for treatment decisions.
August 2003 in “Oncology Times” The trial on testosterone replacement therapy in older men faced concerns due to prostate cancer risk.
2 citations
,
March 2019 in “American journal of physiology. Renal physiology./American journal of physiology. Renal physiology” New treatments targeting fibrosis could improve urinary symptoms in BPH.
10 citations
,
February 2003 in “The Journal of Urology” Surgery, especially prostatectomy, effectively reduces detrusor overactivity in bladder outlet obstruction patients.
3 citations
,
September 2013 in “Urology” More biopsy cores and MRI before biopsy can improve prostate cancer detection.
September 2010 in “Zhonghua miniao waike zazhi” Tamsulosin hydrochloride is safe and effective for long-term treatment of urinary symptoms in BPH patients.
24 citations
,
June 2013 in “Expert opinion on pharmacotherapy” Dutasteride effectively treats benign prostatic hyperplasia but isn't approved for preventing prostate cancer.
December 2016 in “The Journal of urology/The journal of urology” Castration significantly reduces prostate size and BPH symptoms.
January 2019 in “Oncogen” Triple Hormonal Blockade (ADT3) can effectively manage prostate cancer but requires careful monitoring for heart risks.
6 citations
,
June 2022 in “Journal of Clinical Medicine” Tamsulosin with Serenoa repens is as effective as with 5-alpha-reductase inhibitors but causes fewer side effects.
5 citations
,
July 2008 in “The Journal of Urology” 3 citations
,
January 2018 in “Elsevier eBooks” Serenoa repens is a common and effective plant-based treatment for mild-to-moderate prostate enlargement symptoms.
November 2003 in “PubMed”
June 2023 in “Research Square (Research Square)” A higher genetic risk score increases the chance of getting benign prostatic hyperplasia and affects treatment outcomes in Han Chinese men.
32 citations
,
April 2006 in “The Journal of Urology” Using finasteride with TIP extends time off period for prostate cancer patients.
September 2011 in “Urology” The IPP index is linked to storage symptoms and leftover urine, and may help manage urinary tract symptoms.
PRP injections with tadalafil and stretching safely improved Peyronie's symptoms but didn't significantly change curvature long-term.
January 2026 in “Andrology” PRP injections are safe but don't significantly improve Peyronie's Disease.
2 citations
,
August 2021 in “The Journal of Urology” The procedure involving seminal vesiculoscopy, TURED, and balloon dilation effectively treated a man's hematospermia and improved his dysorgasmia.
1 citations
,
October 2008 in “Urology” PSA levels help determine prostate size and guide treatment choices for benign prostatic hyperplasia.
June 2011 in “British Journal of Urology” Regulatory challenges make developing combination therapies in urology difficult and costly.